Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
The HemOnc Pulse
00:00
Exploring Bi-Specific Antibodies in Lymphoma Treatment
Discussion on the challenges of selecting the most suitable bi-specific antibody for lymphoma treatment, considering dosing intervals, therapy durations, patient preferences, and therapy sequencing. Emphasis on shared decision-making, therapy delivery considerations, future prospects, and emerging risks in utilizing bi-specific antibodies.
Transcript
Play full episode
